Anesthesiology, Pain Medicine · Rego Park, NY
NPI
1093974040
Since 2008
Specialty
Anesthesiology, Pain Medicine
Code 207LP2900X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
9701 66th Ave
Rego Park, NY, 11374
Phone (718) 275-5200
Groups this clinician bills Medicare through
Medicare paid, 2024
$333K
5,291 services
Medicare patients, 2024
486
Average age 74
Drug cost, 2024
$923K
5,569 prescriptions
Company payments, 2025
$83.45
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Dmitriy Fuzaylov was code 99213 (office e&m - established), 1,993 times for 419 patients. In total Dmitriy Fuzaylov billed 5,291 services in 71 codes, and Medicare paid $333K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-10-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 1,993 | 419 | $82.62 | $165K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 643 | 124 | $0.76 | $491 |
| 20611 Joint Injection | Office | 309 | 92 | $99.37 | $31K |
| J0702 Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 253 | 127 | $5.57 | $1,409 |
| J7321 Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | Office | 245 | 36 | $57.03 | $14K |
| Q9966 Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | Office | 242 | 50 | $0.29 | $70.76 |
| 99214 Office E&M - Established | Office | 169 | 120 | $114.42 | $19K |
| 97811 Treatment - Miscellaneous | Office | 161 | 26 | $25.12 | $4,044 |
| 97810 Treatment - Miscellaneous | Office | 137 | 26 | $34.11 | $4,673 |
| 99203 Office E&M - New | Office | 122 | 122 | $102.55 | $13K |
| 76942 Ultrasound - Nonspecific | Office | 91 | 76 | $54.29 | $4,940 |
| 95885 Electrical Nerve Conductivity | Office | 69 | 34 | $58.99 | $4,070 |
| J1885 Injection, ketorolac tromethamine, per 15 mg | Office | 69 | 28 | $0.46 | $31.99 |
| 20553 Musculoskeletal | Office | 68 | 60 | $56.20 | $3,822 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 61 | 13 | $0.09 | $5.64 |
By year: 2022 $367K for 9,095 services; 2023 $335K for 5,861 services; 2024 $333K for 5,291 services.
Medicare prescription drug claims, 2024
In 2024, the drug Dmitriy Fuzaylov prescribed most often to Medicare patients was Diclofenac Sodium, with 906 prescriptions and refills. In total Dmitriy Fuzaylov wrote 5,569 Medicare prescriptions that cost $923K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Diclofenac Sodium Generic | 906 | 934 | 206 | $385K |
| Gabapentin Generic | 621 | 655 | 144 | $4,929 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 424 | 424 | 66 | $4,161 |
| Oxycodone Hcl Generic | 368 | 368 | 39 | $4,583 |
| Lidocaine Generic | 237 | 246 | 53 | $22K |
| Meloxicam Generic | 227 | 235 | 108 | $775 |
| Tramadol Hcl Generic | 227 | 227 | 40 | $1,449 |
| Ibuprofen Generic | 183 | 203 | 57 | $527 |
| Baclofen Generic | 171 | 193 | 37 | $1,191 |
| Tizanidine Hcl Generic | 164 | 171 | 31 | $871 |
| Chlorzoxazone Generic | 141 | 141 | 16 | $151K |
| Cyclobenzaprine Hcl Generic | 127 | 129 | 40 | $498 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 120 | 120 | 24 | $1,458 |
| Ztlido Lidocaine | 118 | 118 | 22 | $46K |
| Celecoxib Generic | 113 | 113 | 43 | $1,994 |
Brand drugs: 592 claims; generic drugs: 4,977 claims; opioid claims: 1,415.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Dmitriy Fuzaylov $83.45 ($83.45 in general payments such as food, travel and fees) from 1 company. The largest payer was SPR Therapeutics, Inc with $83.45.
| Company | Payments | Amount |
|---|---|---|
| SPR Therapeutics, Inc | 1 | $83.45 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.